Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
ByGeorgios Evangelou, MD, MSc,Ioannis Vamvakaris, MD, PhD, MSc,Irene Konstantopoulou, PhD,Konstantinos Syrigos, PhD
Published: | Updated:
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
